We hypothesized that the use of a lower vector dose with a codon-optimized SMN1 transgene (co-hSMN1) would restore SMN expression close to physiological levels in relevant organs, providing an improved risk to benefit ratio for SMA patients. Here, SMN1 is linked to proximal spinal muscular atrophy.